Cargando…

Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates

BACKGROUND: A few studies have been carried on preventive drugs for apnea of preterm neonates. OBJECTIVES: This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates. PATIENTS AND METHODS: This study was a randomized clinical trial...

Descripción completa

Detalles Bibliográficos
Autores principales: Armanian, Amir Mohammad, Badiee, Zohreh, Afghari, Raha, Salehimehr, Nima, Hassanzade, Akbar, Sheikhzadeh, Soghra, Sharif Tehrani, Maryam, Rezvan, Gohar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Kowsar 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221998/
https://www.ncbi.nlm.nih.gov/pubmed/25389472
http://dx.doi.org/10.5812/ircmj.12559
_version_ 1782342964024967168
author Armanian, Amir Mohammad
Badiee, Zohreh
Afghari, Raha
Salehimehr, Nima
Hassanzade, Akbar
Sheikhzadeh, Soghra
Sharif Tehrani, Maryam
Rezvan, Gohar
author_facet Armanian, Amir Mohammad
Badiee, Zohreh
Afghari, Raha
Salehimehr, Nima
Hassanzade, Akbar
Sheikhzadeh, Soghra
Sharif Tehrani, Maryam
Rezvan, Gohar
author_sort Armanian, Amir Mohammad
collection PubMed
description BACKGROUND: A few studies have been carried on preventive drugs for apnea of preterm neonates. OBJECTIVES: This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates. PATIENTS AND METHODS: This study was a randomized clinical trial (RCT) research. The prophylactic effect of aminophylline on apnea was investigated in premature babies in our NICU (IRAN-Isfahan). In the study group (A), 5 mg/kg aminophylline was initially administered as a loading dose. Then, every 8 hours, 1.5 mg/kg was given as maintenance dose for the next 10 days. In the control group (C), no aminophylline was used during the first ten days of life. RESULTS: Fifty-two neonates were randomized for the study and all of them completed it. Primary outcomes were clearly different between the two groups. Only 2 infants (7.7%) who had been placed in aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001). Median time of need to NCPAP (Nasal Continuous Positive Airway Pressure) was 1 (0 - 4) days and 2.5 (0.5 - 6.5) days in group A and C, respectively (P = 0.03). No side effects were reported in neonates (P > 0.999). Median time of hospitalization was shorter in aminophylline group (P = 0.04). CONCLUSIONS: This study supports the preventative effects of aminophylline on apnea in extreme premature infants. In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia.
format Online
Article
Text
id pubmed-4221998
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Kowsar
record_format MEDLINE/PubMed
spelling pubmed-42219982014-11-11 Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates Armanian, Amir Mohammad Badiee, Zohreh Afghari, Raha Salehimehr, Nima Hassanzade, Akbar Sheikhzadeh, Soghra Sharif Tehrani, Maryam Rezvan, Gohar Iran Red Crescent Med J Research Article BACKGROUND: A few studies have been carried on preventive drugs for apnea of preterm neonates. OBJECTIVES: This study aimed to assess the safety and prophylactic effects of aminophylline on the incidence of apnea in premature neonates. PATIENTS AND METHODS: This study was a randomized clinical trial (RCT) research. The prophylactic effect of aminophylline on apnea was investigated in premature babies in our NICU (IRAN-Isfahan). In the study group (A), 5 mg/kg aminophylline was initially administered as a loading dose. Then, every 8 hours, 1.5 mg/kg was given as maintenance dose for the next 10 days. In the control group (C), no aminophylline was used during the first ten days of life. RESULTS: Fifty-two neonates were randomized for the study and all of them completed it. Primary outcomes were clearly different between the two groups. Only 2 infants (7.7%) who had been placed in aminophylline group developed apnea, as compared to 16 infants (61.5%) in the control group (P < 0.001). Three and four neonates (11.5%, 15.4%) in the aminophylline group developed bradycardia and cyanosis respectively, as compared to 16 infants (61.5%) who did not receive aminophylline (P < 0.001). Median time of need to NCPAP (Nasal Continuous Positive Airway Pressure) was 1 (0 - 4) days and 2.5 (0.5 - 6.5) days in group A and C, respectively (P = 0.03). No side effects were reported in neonates (P > 0.999). Median time of hospitalization was shorter in aminophylline group (P = 0.04). CONCLUSIONS: This study supports the preventative effects of aminophylline on apnea in extreme premature infants. In other words, the more premature an infant, the greater the preventative effect of aminophylline on the incidence of apnea and bradycardia. Kowsar 2014-08-05 2014-08 /pmc/articles/PMC4221998/ /pubmed/25389472 http://dx.doi.org/10.5812/ircmj.12559 Text en Copyright © 2014, Iranian Red Crescent Medical Journal; Published by Kowsar Corp. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Armanian, Amir Mohammad
Badiee, Zohreh
Afghari, Raha
Salehimehr, Nima
Hassanzade, Akbar
Sheikhzadeh, Soghra
Sharif Tehrani, Maryam
Rezvan, Gohar
Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title_full Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title_fullStr Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title_full_unstemmed Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title_short Prophylactic Aminophylline for Prevention of Apnea at Higher-Risk Preterm Neonates
title_sort prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4221998/
https://www.ncbi.nlm.nih.gov/pubmed/25389472
http://dx.doi.org/10.5812/ircmj.12559
work_keys_str_mv AT armanianamirmohammad prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT badieezohreh prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT afghariraha prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT salehimehrnima prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT hassanzadeakbar prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT sheikhzadehsoghra prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT shariftehranimaryam prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates
AT rezvangohar prophylacticaminophyllineforpreventionofapneaathigherriskpretermneonates